NEONC TECHNOLOGIES HOLDINGS, INC.
NTHINasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | |
|---|---|---|
| Revenue | $39,990 | $83,000 |
| Operating income | −$58.2M | −$7.1M |
| Net income | −$62.1M | −$11.9M |
| Total assets | $2.8M | $3.4M |
| Total liabilities | $20.3M | $8.9M |
| Equity | −$17.5M | −$5.5M |
| EPS (diluted) | $-3.20 | $-0.69 |
| Shares out. | 22.0M | 18.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −145637.5%
- Net margin
- −155404.4%
- Return on equity
- 355.0%
- Return on assets
- −2200.9%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 720.0%
- Debt / equity
- —
- Book value / share
- $-0.80
- Revenue growth (YoY)
- −51.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -313.02distress
- Accruals / assets
- −1479.7%clean
- Piotroski F-Score
- 1/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2025
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1/2Recruitingreadout ~2026-03-30Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- Phase 1Not Yet Recruitingreadout ~2026-10A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
- Phase 2Recruitingreadout ~2026-12-30NEO100 and High-Grade Meningioma
- Phase 1/2Recruitingreadout ~2027-02-28Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Cinctive Capital Management LpPassive (13G)May 15, 2026
- Heshmatpour Amir FActivist (13D)Apr 25, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Heshmatpour Amir FOfficer — President | May 1, 2026 | Buy | 10,000 | $4.16 |
| Heshmatpour Amir FOfficer — President | Apr 28, 2026 | Buy | 10,000 | $4.52 |
| Neman-Ebrahim YoushaOfficer — Chief Clinical Officer | Apr 23, 2026 | Buy | 500 | $4.88 |
| Garnett KeithlyOfficer — CFO | Apr 15, 2025 | Buy | 300 | $5.38 |
| Heshmatpour Amir FOfficer — President | Apr 23, 2026 | Buy | 10,000 | $4.90 |
| Suh, David Jr.Officer — Chief Accounting Officer | Mar 1, 2026 | Grant | 111,666 | — |
| Heshmatpour Amir FOfficer — President | Apr 10, 2026 | Buy | 10,000 | $4.89 |
| Heshmatpour Amir FOfficer — President | Apr 8, 2026 | Buy | 10,000 | $5.61 |
| Heshmatpour Amir FOfficer — President | Apr 2, 2026 | Buy | 20,000 | $6.09 |
| Heshmatpour Amir FOfficer — President | Nov 21, 2025 | Buy | 20,000 | $5.98 |
| Neman-Ebrahim YoushaOfficer — Chief Clinical Officer | Nov 20, 2025 | Buy | 1,100 | $6.69 |
| Heshmatpour Amir FOfficer — President | Nov 6, 2025 | Grant | 1.2M | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 234,196 | 1.7 | -14.8% |
| Apr 30, 2026 | 274,795 | 3.9 | -24.5% |
| Apr 15, 2026 | 363,971 | 6.3 | +25.6% |
| Mar 31, 2026 | 289,781 | 8.9 | +23.2% |
| Mar 13, 2026 | 235,277 | 5.8 | +9.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operations · Regulation FD disclosureMay 18, 2026
- Entered a material agreement · Unregistered equity saleApr 24, 2026
- Regulation FD disclosureApr 16, 2026
- Entered a material agreementApr 10, 2026
- Results of operations · Regulation FD disclosureApr 3, 2026
- Entered a material agreement · Unregistered equity saleMar 23, 2026
- Entered a material agreement · Director / officer change · Regulation FD disclosureMar 17, 2026
- Regulation FD disclosureMar 6, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KMay 18, 2026
- SCHEDULE 13GMay 15, 2026
- 10-QMay 15, 2026
- 10-K/AMay 5, 2026
- 4PRIMARY DOCUMENTMay 4, 2026
- 4PRIMARY DOCUMENTApr 28, 2026
- 4PRIMARY DOCUMENTApr 24, 2026
- 4PRIMARY DOCUMENTApr 24, 2026
- 8-KApr 24, 2026
- 4PRIMARY DOCUMENTApr 23, 2026
- EFFECTApr 16, 2026
- 8-KApr 16, 2026
- 424B5Apr 16, 2026
- CORRESPApr 14, 2026
- UPLOADApr 14, 2026